| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02833506 Details | 2018-05-01 Interventional | 1 | 0 | Sirolimus Carcinoma Carcinoma, Ovar… Fallopian Tube … Ovarian Neoplas… Peritoneal Neop… Recurrence Recurrent Fallo… Recurrent Ovari… Recurrent Prima… Stage IIA Fallo… Stage IIA Ovari… Stage IIB Fallo… Stage IIB Ovari… Stage IIC Fallo… Stage IIC Ovari… Stage IIIA Fall… Stage IIIA Ovar… Stage IIIA Prim… Stage IIIB Fall… Stage IIIB Ovar… Stage IIIB Prim… Stage IIIC Fall… Stage IIIC Ovar… Stage IIIC Prim… Stage IV Fallop… Stage IV Ovaria… Stage IV Primar… | production of adjuvant to be used with vaccine was discontinued by sponsor - | |||
| NCT03417037 2017-003058-18 Details | 2018-04-30 Interventional | 3 | 0 | Linrodostat Nivolumab Carcinoma, Non-… Lung Neoplasms Lung Cancer Non-Small Cell … | Business objectives have changed. - | |||
| NCT02877082 Details | 2018-04-30 Interventional | 2 | 5 | Antilymphocyte … Bortezomib Tacrolimus Thymoglobulin Graft vs Host D… Leukemia Leukemia, Lymph… Leukemia, Myelo… Leukemia, Myelo… Lymphoma Lymphoma, Large… Lymphoma, Mantl… Myelodysplastic… Myeloproliferat… Acute Leukemia Chronic Lymphoc… Chronic Myeloge… Diffuse Large B… Follicular Lymp… Graft Versus Ho… Mantle Cell Lym… Marginal Zone L… Myelodysplastic… Myelofibrosis Myeloproliferat… Small Lymphocyt… | - After monitoring early toxicity and hyperacute severe acute graft versus host disease in 4/5 patients, it was decided to close this protocol. | |||
| NCT02543645 Details | 2018-04-30 Interventional | 1 | 18 | Atezolizumab Carcinoma Carcinoma, Rena… Kidney Diseases Kidney Neoplasm… Neoplasms Neoplasms by Hi… Triple Negative… Urogenital Neop… Urologic Diseas… Urologic Neopla… Bladder Cancer Clear-cell Meta… Head and Neck C… Melanoma Non-small Cell … Triple Negative… | Portfolio re-prioritization - | |||
| NCT03335501 Details | 2018-04-27 Interventional | 2 | 0 | Hormones Pancrelipase Diabetes Mellit… Type 1 Diabetes… | The owner of the algorithm does not wish that this study be undertaken - | |||
| NCT03023904 Details | 2018-04-25 Interventional | 2 | 0 | Nivolumab Carcinoma, Non-… Lung Neoplasms Recurrence Recurrent Non-S… Stage IV Non-Sm… | Research cancelled - | |||
| NCT02829814 Details | 2018-04-25 Interventional | 3 | 51 | Cyclobenzaprine Collagen Diseas… Fibromyalgia Muscular Diseas… Musculoskeletal… Myofascial Pain… Nervous System … Neuromuscular D… Rheumatic Disea… | For business reason unrelated to safety or tolerability,Tonix has discontinued the Fibromyalgia
development with TNX102 SL. - | |||
| NCT02589275 Details | 2018-04-25 Interventional | 3 | 375 | Cyclobenzaprine Fibromyalgia Myofascial Pain… Primary Fibromy… | For business reason unrelated to safety or tolerability,Tonix has discontinued the Fibromyalgia
development with TNX102 SL. - | |||
| NCT02296840 Details | 2018-04-25 Interventional | 4 | 45 | Acetaminophen Acetaminophen, … Hydrocodone Ibuprofen Drug-Related Si… Sleep Apnea Syn… Sleep Apnea, Ob… Tonsillitis Adverse Reactio… Obstructive Sle… Recurrent Tonsi… Sleep Disordere… | - Many participants did not completed the pain control survey, limiting the conclusions that can be made from this study. | |||
| NCT00626626 Details | 2018-04-25 Interventional | 1/2 | [1 Refs] | 8 | Alemtuzumab Clofarabine Cyclophosphamid… Leukemia Leukemia, Myelo… Leukemia, Myelo… Lymphoma Multiple Myelom… Myelodysplastic… Preleukemia Chronic Myeloge… Hodgkin's Lymph… Myelodysplastic… | Investigator decision - | ||
| NCT02379585 Details | 2018-04-24 Interventional | 1/2 | 8 | Cyclophosphamid… Docetaxel Doxorubicin Paclitaxel Pertuzumab Trastuzumab Breast Neoplasm… HER2-positive B… | PI Decision - | |||
| NCT02002377 Details | 2018-04-24 Interventional | 4 | 23 | Aflibercept Macular Degener… Age Related Mac… | Inadequate enrollment due to investigational product becoming newly available on the Canadian
market soon after study start - | |||
| NCT01331824 Details | 2018-04-23 Interventional | 2 | 22 | Amrubicin Carcinoma, Tran… Urinary Bladder… Bladder Cancer | due to a development decision by the funder The trial was terminated prematurely due to the results of a phase 3 study seeking registration for amrubicin in small cell lung cancer in the United States, leading the industry funder to discontinue further clinical development of amrubicin. | |||
| NCT00796328 Details | 2018-04-23 Interventional | 4 | 45 | Oxymetazoline Phenylephrine Hypotension Spinal Induced … | Results Invalid, study closed, analysis cannot proceed. - | |||
| NCT00977405 Details | 2018-04-20 Interventional | 2 | [1 Refs] | - | Gentamicins Surgical Wound … Superficial Sur… | - - | ||
| NCT00459108 Details | 2018-04-19 Interventional | 2 | 25 | Dasatinib Carcinoma Carcinoma, Hepa… Liver Neoplasms Adult Primary H… Advanced Adult … Recurrent Adult… | Halted early for futility. Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results. | |||
| NCT03253224 Details | 2018-04-18 Interventional | 4 | 24 | Magnesium Sulfa… Pain, Postopera… Arthritis Knee Dexmedetomidine Magnesium Sulfa… | Because the principle investigator will participate a visiting scholar program for one year in
other country, this study has been terminated. - | |||
| NCT02462265 Details | 2018-04-18 Interventional | 2 | - | Antineoplastic … Mitoxantrone Leukemia Leukemia, Lymph… Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… Lymphoid Leukem… | - - | |||
| NCT03498534 Details | 2018-04-17 Interventional | 4 | 0 | Isoniazid Diabetes Mellit… Latent Tubercul… Tuberculosis | Due to administrative procedures - | |||
| NCT03069768 Details | 2018-04-17 Interventional | 1 | 0 | Varenicline Tobacco Use Dis… Nicotine Depend… | Unable to obtain varenicline to provide to participants - |